Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 32 of 1124 for:    migraine

To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03777059
Recruitment Status : Recruiting
First Posted : December 17, 2018
Last Update Posted : October 2, 2019
Sponsor:
Information provided by (Responsible Party):
Allergan

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 5, 2020
Estimated Study Completion Date : February 5, 2020